Yuanfa Lian

Title: Innovations of Yuanfa Lian in Pharmaceutical Technology

Introduction

Yuanfa Lian is a notable inventor based in Guangzhou, China. He has made significant contributions to the field of pharmaceutical technology, particularly in the development of innovative drug formulations. With a total of 2 patents, his work focuses on enhancing the efficacy and stability of drug delivery systems.

Latest Patents

Yuanfa Lian's latest patents include a preparation method of sustained-release microparticles. This invention allows for the entire preparation process to occur at normal or low temperatures, which is particularly beneficial for high-temperature-sensitive drugs such as proteins, nucleic acids, and peptides. The sustained-release microparticles exhibit an excellent release profile, maintaining drug concentration stability and overcoming limitations of conventional methods.

Another significant patent is the targeted hydrophobic anti-tumor drug nanoformulation and its preparation method. This formulation consists of a hydrophobic anti-tumor drug combined with a carrier in a specific mass ratio. The carrier is made up of albumin and a hyaluronic acid-albumin conjugate, ensuring even particle size distribution and good dispersibility. The nanoformulation demonstrates high yield and efficacy, making it a promising advancement in targeted cancer therapies.

Career Highlights

Yuanfa Lian is currently associated with Ac Pharmaceuticals Co., Ltd., where he continues to innovate in drug formulation technologies. His work has been instrumental in developing new methods that enhance the delivery and effectiveness of therapeutic agents.

Collaborations

Yuanfa has collaborated with notable colleagues such as Feng Liu and Fuchun Cao, contributing to the advancement of pharmaceutical research and development.

Conclusion

Yuanfa Lian's contributions to pharmaceutical technology through his innovative patents highlight his role as a leading inventor in the field. His work not only improves drug delivery systems but also paves the way for future advancements in targeted therapies.